Taking aim with innovation + experience

Advanced science meets advanced development: gain access to the innovative vault of antibody assets

Contact Us

Browse our innovative pipeline

From our novel oncology programs to taking aim at vascular disease, find the answers to some of your largest pharma challenges. Talem has leveraged its expertise in antibody discovery and development to establish an innovative pipeline of next-generation antibody therapeutics for multiple disease indications. 

Talem Programs are available for licensing and partnership.

Talem Antibody Therapeutics Pipeline

Program ID
Target: CAXII | Indication: IO, ONC | Lead Candidate Selection
  • TATX-20
  • IO, ONC

Expression of the membrane protein carbonic anhydrase XII (CAXII) is induced under hypoxic conditions in solid tumors. CAXII enzymatic activity is crucial for the survival and proliferation of cancer cells, resulting in tumor establishment, homeostasis, and metastasis. In addition, CAXII is required for Pgp-mediated resistance to chemotherapy. CAXII is overexpressed on various cancers such as renal, breast, colon, cervical and ovarian. Importantly, inhibition of CAXII activity has been shown to reduce tumor size, inhibit tumor migration, and to restore sensitivity to chemotherapy in preclinical models. Therefore, Talem has developed an antagonistic, fully human monoclonal antibody highly specific for CAXII. Talem focuses on the development of a lead candidate for the treatment of ovarian cancer due to the high unmet medical need, paucity of immunotherapeutic options, high recurrence rate, and frequent occurrence of resistance to chemotherapy.



Format: Monoclonal antibody

Stage: Lead candidate

Mode of action: Inhibition of enzymatic activity

Indication: Solid tumors, focus on ovarian cancer

Target: CD3 | Indication: IO | Lead Candidate Selection
  • TATX-24
  • CD3
  • IO

Many solid tumors are poorly immunogenic as the binding of monoclonal antibodies to the tumor associated antigen (TAA) often fails to induce the required immune response for tumor cell killing. This renders immunotherapy less effective. Combining anti-TAA binding capability with anti-CD3 T cell engagement into one bispecific molecule enables the recruitment and activation of T cells to increase immunotherapy efficacy. The first generation of T cell engagers available on the market have a high affinity for CD3 and induce potent tumor cell killing, but also cause the release of high levels of cytokines, leading to severe side effects and a narrow therapeutic window. Talem has developed anti-CD3 Fabs specifically directed against CD3δε, which are expected to reduce cytokine release. These Fabs are available to combine with anti-TAA arms of potential partners for the generation of novel T cell engaging bi-, tri- and multi- specific molecules.


TATX-24: CD3δε Fabs

Format: CD3δε targeting fragment antigen-binding (Fab) arm for a bi- or multi-specific

Stage: Lead candidate

Mode of action: T cell engagement

Focused indication: Bi-, tri- and multi-specifics

Target: Undisclosed | Indication: IO, ONC | Lead Candidate Selection | Partner: Pierre Fabre
  • TATX-25
  • Undisclosed
  • IO, ONC


Pierre Fabre
Target: B7-H3 | Indication: IO | Lead Candidate Selection | Partner: undisclosed
  • TATX-28
  • B7-H3
  • IO


Target: TrkB | Indication: IO, ONC | Lead Candidate Selection
  • TATX-112
  • TrkB
  • IO, ONC

Tropomyosin receptor kinase B (TrkB) is a receptor tyrosine kinase (TK) that is implicated in various solid tumors.
Ordinarily, TrkB expression is confined to the central nervous system where it is important for maintaining normal
brain function. Aberrant and overexpression of TrkB is implicated in various solid malignancies and associated with poor prognosis. Currently, therapeutic options for TrkB targeting are restricted to pan-Trk inhibitors, which lack specificity and cause side effects. The use of monoclonal
antibodies specifically binding TrkB for the intracellular delivery of toxic payloads (i.e. ADC) is anticipated to increase safety and efficacy of TrkB-directed cancer therapies. Additionally, large molecules, such as antibodies, do not readily cross the blood-brain-barrier, further reducing the risk of on-target side effects. Highly specific anti-TrkB internalizing antibodies are being developed to combine with ADC platform technologies of potential partners.


TATX-112: TrkB

Format: Monoclonal antibody for ADC-based therapeutics

Stage: Lead selection

Mode of action: Internalization for delivery of toxic payload into tumor cells

Indication: Solid tumors

Target: TrkBxCD3 | Indication: IO, ONC | Lead Candidate Selection
  • TATX-200
  • TrkBxCD3
  • IO, ONC

Breast cancer (BC) accounts for 30% of all new female cancer cases each year. While there are good treatment options available, there are still hard to treat or unresponsive subtypes of BC, such as triple negative BC (TNBC). The (over)expression of the Tropomyosin kinase B (TrkB) and (over)activation of the TrkB signaling pathway play an important role in various solid malignancies, including BC, and are associated with poor prognosis. Preclinical studies have demonstrated that targeting the TrkB pathway can reduce BC cell growth and metastasis, but current TrkB-directed treatment options are not specific. Additionally, breast tumors are not highly immunogenic, rendering immunotherapy less effective. By combining Talem’s proprietary anti-TrkB antibody arms with proprietary anti-CD3δε T cell engaging antibody arms in a bispecific format, a novel and effective immunotherapeutic molecule against BC is being developed with the aim of improving therapeutic options.


TATX-200: TrkBxCD3 Bispecific Antibodies

Format: Bispecific antibody, T cell engager

Stage: Lead candidate

Mode of action: T cell engagement

Indication: Breast cancer (TNBC, HER2 neg.) and other solid tumors

Target: SARS-CoV-2 | Indication: ID | Lead Candidate Selection
  • TATX-03
  • SARS-CoV-2
  • ID
  • PolyTope®

One of Talem’s most advanced development programs, TATX-03 (anti-SARS-CoV-2 PolyTope), is a rationally designed, fully human, 4-antibody combinational therapy containing synergistic, potently neutralizing monoclonal antibodies against non-overlapping epitopes on SARS-CoV-2 spike trimer. Talem’s SARS-CoV-2 PolyTope therapy is designed to reduce mutagenic escape risk with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2, and has been developed with the goal of sustainable efficacy as the virus evolves, combining broadly characterized, neutralizing and synergistic antibodies that exhibit diverse epitope coverage.


TATX-03: “PolyTope®”

Format: Multi-antibody combination Tx

Stage: IND enabling/drug product manufacturing complete

Target: SARS-CoV-2 and its variants

Target: ALK1 | Indication: OP/VD | Lead Candidate Selection
  • TATX-21
  • ALK1
  • OP/VD

Activin receptor-like kinase 1 (ALK1), a member of the TGF-β receptor superfamily, is preferentially expressed on endothelial cells. Its ligands are BMP9 and BMP10. Impaired BMP9/ALK1 signaling is associated with various vascular pathologies such as diabetic retinopathy, diabetic kidney problems and pulmonary arterial hypertension (PAH); all chronic and hard to treat conditions. Enhancing signaling via the BMP9/ALK1 pathway has been demonstrated to reduce symptoms associated with PAH and to prevent hyperglycemia-induced vascular permeability in preclinical animal models. Enhancing ALK1-signaling by treatment with BMP9 carries the risk of side effects through interaction with its other cognate receptors. Therefore, Talem is developing agonist antibodies specific for ALK1 with the aim to generate a safe and effective therapeutic for these vascular pathologies.



Format: Monoclonal antibody

Stage: Lead Candidate Selection

Mode of action: Stimulation of signaling (agonist)

Indications: Diabetic retinopathy and pulmonary arterial hypertension

INDICATION KEY: ID= Infectious Disease | IO= Immuno-Oncology | ONC = Oncology | OP= Ophthalmology | VD= Vascular Disease
out-license   Available for out-license


This information was factually accurate on the date it was published. Talem assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Talem pipeline, readers should visit the News section of our website or connect with us. This information constitutes forward-looking statements relating to Talem’s business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Talem Therapeutics LLC regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the ImmunoPrecise Antibodies Ltd. Group’s ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in ImmunoPrecise Antibodies’ current Form 40-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Out-license partnership opportunity

Creating clinical success together

We are flexible in exploring a variety of partnerships to fully harness the potential of our innovative robust pipeline prospects.

Partnership Opportunities

  • Out-licensing of Talem’s pipeline assets
  • Collaborations to explore novel combinations with Talem’s pipeline assets for licensing
  • Strategic alliances and collaborations to identify and develop novel antibody therapeutics to advance partner’s pipeline

Let’s connect today to create a healthier tomorrow.

Contact us

Register for future communications

By clicking submit below, you agree that Talem and IPA may store and process your personal information to send you email updates. You can find further information in our Privacy Policy.

Connect with us